JAM3 and systemic sclerosis: As far as ischemic DUs are concerned, the circulating levels of both sJAM-A and sJAM-C were found to be significantly higher when compared to controls both in SSc patients with DUs (median 1.01 ng/mL, IQR 0.00–2.37 ng/mL for sJAM-A and median 0.84 ng/mL, IQR 0.54–3.58 ng/mL for sJAM-C; p < 0.001 for both molecules; Figure 4A,B) and in those without DUs (median 0.53 ng/mL, IQR 0.00–1.12 ng/mL for sJAM-A and median 0.47 ng/mL, IQR 0.34–0.82 ng/mL for sJAM-C; p = 0.003 for sJAM-A and p < 0.001 for sJAM-C; Figure 4A,B).